OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million

OPTIMIZERx Corp. (NASDAQ:OPRX), a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the consensus of $30.36 million.

The company reported adjusted EPS of 30 cents, beating the analyst’s estimate of 27 cents.

Full-year revenue increased 29% year-over-year, reaching $92.1 million. The company’s gross profit climbed 23% in the fourth quarter to $22 million, with full-year gross profit totaling $59.4 million.

Adjusted EBITDA demonstrated significant growth, increasing 53% year-over-year in the fourth quarter to $8.8 million. For the full year, adjusted EBITDA reached $11.7 million.

OptimizeRx ended 2024 with $13.4 million in cash and cash equivalents, with net cash provided by operating activities totaling $4.9 million.

Also Read: What’s Going On With Baker Hughes Stock Today?

“With the strong tailwinds we saw at the end of 2024 and into the start of 2025, we believe we are uniquely positioned to grow shareholder value by leveraging our industry leadership position in addressing pharma’s most critical commercial challenges: improving brand visibility in an increasingly digital healthcare environment, reducing script abandonment rates, enhancing interoperability at the point of care, and supporting the shift toward complex specialty medications,” OptimizeRx CEO Stephen L. Silvestro said.

Key performance indicators reflected the company’s strong relationships with major pharmaceutical manufacturers.

• The top 20 pharmaceutical companies accounted for 64% of total revenue, with an average revenue per top manufacturer of $2.93 million, up from $2.4 million in 2023.
• The company maintained a 100% penetration rate among these top pharmaceutical clients and improved its net revenue retention to 121%, compared to 105% in the prior year.

Guidance: OptimizeRx expects continued growth in 2025, forecasting revenue of at least $100 million versus a consensus of $99.65 million and an adjusted EBITDA of at least $12 million.

OPRX Price Action: OptimizeRx stock is up 40.78% at $5.83 at publication Wednesday.

Read Next:

• Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs

Photo: Shutterstock